Atlas5D announces $3 MM Series A from GreyBird Ventures

CAMBRIDGE, MA – Atlas5D, a leader in creating solutions to help people with reduced mobility live better and richer lives, announced a $3 million Series A venture capital investment from GreyBird Ventures, LLC, a venture firm that invests in early-stage companies developing products to accelerate the nascent trend of precision medicine. Atlas5D will use the infusion of capital to continue growing its team and expanding the business. Atlas5D develops ambient sensors to precisely quantify aspects of human motion and behavior, such as speed and strength. The populations served range from very young to very old, encompass a wide variety of...

Hummingbird Diagnostics & Saarland University Cooperate on Cancer Detection

Hummingbird Diagnostics & Saarland University cooperate on the early detection of cancer by liquid biopsy employing miRNA fingerprints Early detection as key for improved outcome The maybe best strategy in the daily fight against cancer – besides preventive actions such as anti-smoking campaigns – is the in-time detection of malignant tumors. There is an undisputed clinical need for minimally or non-invasive diagnostics that facilitate sensitive and specific discovery of cancers. The panel of possible approaches that is currently explored by research groups and companies worldwide includes different molecular diagnostic options, including protein patterns, gene expression profiles, epigenetics or metabolic marker...

Atlas5D announces collaboration with Biogen

Biogen is one of the world’s leading biotechnology companies, with a focus on developing therapies for neurodegenerative, hematologic and autoimmune disorders. Founded in 1978, Biogen’s work in biologics and small-molecule drug discovery has led to the world’s most extensive portfolio of multiple sclerosis (MS) therapies and innovative new treatments for hemophilia patients. Biogen seeks to enhance individualized treatment outcomes through emerging technology, clinical innovation, and continuous learning. Biogen’s work aims to capitalize on new and emerging technology to collect and better synthesize information in order to improve knowledge of disease impacts and therapies. Biogen became interested in Atlas5D’s technology, Echo5D,...

1 3 4 5
GreyBird Ventures

is named after the arctic tern, a bird that migrates 71,000 km annually. As they can live for 30 years, this is the lifetime equivalent of three trips to the moon and back. Not bad for a 100 gram bird. We strive to emulate its size to performance ratio as well as its global reach.


For additional information, please contact: